Best AI Medical Diagnostic Platforms in 2026

The best AI medical diagnostic platforms in 2026 are Viz.ai for stroke detection and care coordination, Aidoc for enterprise imaging AI orchestration, and Qure.ai for chest X-ray, head CT and TB screening. No single platform is best for every diagnostic job, and FDA clearance covers a specific device, indication and version, not a whole company.

Buyers are often comparing tools that do very different clinical jobs and rest on very different evidence. Most vendors publish no prices, and most performance figures come from the vendors themselves. Clearance counts can even conflict within a single vendor’s own materials.

PlugRoute has no affiliate relationships with any company listed, and rankings are determined entirely by research data and objective evaluation criteria.

“Everything I have used so far just slows me down.” (Radiologist, r/radiologyAI, 2026)

Takeaway: Results from AI diagnostic tools vary from site to site. Buyers should treat published performance as a starting point for local validation, not a guarantee.

What Are the 6 Categories of AI Medical Diagnostic Tools?

AI medical diagnostic tools fall into six categories, and only some of them are FDA-cleared diagnostic devices. The category determines what evidence and regulatory checks apply, so buyers should identify it before comparing vendors. This guide defines consumer symptom checkers below but does not rank them.

• Orchestrator: An Orchestrator is an enterprise layer that sends imaging exams to multiple AI models and governs them in one workflow. Aidoc is the ranked Orchestrator.
• Detect-and-Coordinate: A Detect-and-Coordinate platform flags suspected time-critical findings and then coordinates the care team’s response. Viz.ai is the ranked Detect-and-Coordinate platform.
• Imaging Point Solution: An Imaging Point Solution provides FDA-cleared AI for specific findings on specific imaging modalities. Qure.ai is the ranked Imaging Point Solution.
• Pathology Platform and AI: A Pathology Platform and AI product combines whole-slide image viewing with pathology algorithms. PathAI and Paige are the ranked pathology products.
• Clinical Decision Support (Non-Device): A Clinical Decision Support (Non-Device) tool helps clinicians reason through cases but is not an FDA-cleared diagnostic device. OpenEvidence and Isabel DDx Companion are the ranked decision-support tools.
• Consumer Symptom Checker (not ranked): A Consumer Symptom Checker gives laypeople possible conditions and triage advice. This guide covers symptom checkers only in a separate safety section.

How Do the Top AI Medical Diagnostic Platforms Compare at a Glance?

Viz.ai, Aidoc and Qure.ai lead on verified regulatory scope and deployment. OpenEvidence and Isabel DDx Companion are decision-support tools, not cleared devices. PathAI and Paige both need a fully digitized pathology workflow. Every product below has a real limitation, and the right choice depends more on the clinical job than on overall rank.

Rank	Company	Category	Best For	One-Line Summary	Key Capabilities	Primary Strength	Key Limitation
1	Viz.ai (Viz.ai One)	Detect-and-Coordinate	Hub-and-spoke stroke networks	Viz.ai is a stroke-focused AI detection and care-coordination platform whose independently supported strength is faster treatment workflows.	LVO detection, mobile alerts, care-team messaging, 50+ pathways (vendor-reported)	Faster workflow times linked to Viz.ai use in a 2025 meta-analysis	No significant length-of-stay change; NICE found evidence insufficient
2	Aidoc (aiOS + CARE)	Orchestrator	Health systems running many imaging algorithms	Aidoc is an enterprise imaging AI orchestration platform with the broadest explicitly listed acute-imaging clearances in this review.	aiOS routing, third-party algorithm hosting, 14-indication abdominal CT triage	Broad clearances plus hosting for other vendors’ models	Outcome figures vendor-reported; clearance counts conflict
3	Qure.ai (qXR, qER, qCT)	Imaging Point Solution	Chest X-ray, head CT, TB screening	Qure.ai is a chest and head imaging AI vendor with product-specific FDA clearances and independent TB-screening evidence.	Chest X-ray, head CT and lung-nodule products	Product-level regulatory page; highest AUC in one 5-system TB test	48.7% specificity at 95.5% sensitivity (expert reader: 42.2%)
4	OpenEvidence	Clinical Decision Support (Non-Device)	Individual clinicians	OpenEvidence is a free, ad-supported LLM evidence tool that is not an FDA-cleared diagnostic device.	Cited Q&A, licensed NEJM/JAMA content, DeepConsult, Visits	Free access; highest review volume	13.3% misapplied-source rate in one 2026 implant-dentistry study
5	Isabel DDx Companion	Clinical Decision Support (Non-Device)	Clinicians and trainees who want predictable cost	Isabel DDx Companion is a structured, non-LLM differential-diagnosis engine with fully public pricing.	10,000+ conditions, “don’t miss” flags, optional LLM summary	Public pricing; consistent non-LLM output	Top-ten rate fell to 28% in a 2025 independent rare-disease study
6	PathAI (AISight Dx)	Pathology Platform and AI	Labs going digital	PathAI AISight Dx is an FDA-cleared digital pathology viewing platform whose AI algorithms are mostly Research Use Only in the US.	Whole-slide viewer (K243391), third-party app hosting	Verified 2025 510(k)	Key algorithms are Research Use Only
7	Paige (Tempus)	Pathology Platform and AI	Digital labs with prostate biopsy volume	Paige Prostate Detect is the first FDA-authorized AI pathology product, cleared only as a narrow prostate-biopsy adjunct.	Prostate Detect, FullFocus viewer, Virchow model	First AI pathology De Novo (2021)	Narrow indication; study figures unverified

Which AI Diagnostic Platform Should I Choose for My Clinical Job?

Buyers should choose an AI diagnostic platform by clinical job and prerequisite, not by overall rank. A stroke network needs different evidence than a pathology lab or an individual clinician does. The table below matches each priority to a recommended tool, gives the reason and any prerequisite, and names an acceptable alternative.

Your #1 Priority	Recommended Tool	Why	Acceptable Alternative
Stroke program with a hub-and-spoke network	Viz.ai	A 2025 meta-analysis linked Viz.ai use to faster door-to-groin times; requires a transfer network	RapidAI (not ranked; run a local head-to-head)
Many acute-imaging algorithms under one governance layer	Aidoc	Hosts Aidoc, partner and homegrown algorithms; requires PACS and worklist integration	Qure.ai for defined chest/head CT use cases
Chest X-ray, TB or lung screening	Qure.ai	Product-specific clearances and independent TB evaluations; requires local threshold tuning	Annalise.ai or Lunit (not ranked)
Free evidence lookup for individual clinicians	OpenEvidence	Free, cited answers; requires a security review before any PHI	Isabel DDx Companion
Structured differential with predictable cost	Isabel DDx Companion	Public pricing; consistent, non-LLM output	OpenEvidence
Cleared digital pathology viewer that hosts multiple apps	PathAI AISight Dx	2025 510(k) and third-party hosting; requires digitized WSI on a cleared scanner	Paige FullFocus
Prostate biopsy AI adjunct in a digital lab	Paige Prostate Detect	First FDA-authorized AI pathology software; requires a cleared scanner	PathAI AISight Dx hosting Paige apps
Consumer symptom questions	See a clinician	Symptom checkers are information aids only	None ranked

Regulatory, Evidence and Pricing Snapshot

Company	Regulatory Status	Highest Evidence Tier	Pricing Model
Viz.ai	Viz LVO De Novo (2018); 13 clearances reported, not reconciled with public FDA records	Tier 1 (2025 meta-analysis; NICE)	Quote-only; NTAP history
Aidoc	Multiple 510(k)s; CARE foundation-model clearances (2025–2026); Breakthrough designation (not an authorization)	Tier 2 (pivotal study); Tier 1 negative (NICE)	Quote-only
Qure.ai	7 cleared products on its regulatory page; TB screening falls under WHO’s category-level CAD recommendation and is not FDA-cleared	Tier 1 (multi-product TB evaluations)	Custom
OpenEvidence	Not FDA-cleared	Tier 2 (independent evaluation)	Free, ad-supported
Isabel DDx Companion	Not a cleared device	Tier 2 (independent 2025 rare-disease study; vendor-listed accuracy studies)	Public: $149–$199/year
PathAI	AISight Dx 510(k) K243391 (2025); key algorithms Research Use Only	Tier 3 (vendor-reported)	Quote-only plus digitization
Paige	Prostate Detect De Novo DEN200080 (2021); PanCancer Detect has Breakthrough designation only	Tier 3 (circulating study figures unverified; De Novo pivotal data not reviewed)	Not public plus digitization

What Are the Best AI Medical Diagnostic Platforms, Ranked?

PlugRoute ranked the seven platforms below by weighted scores on six published criteria, led by regulatory scope and independent evidence. Viz.ai ranks first on independent evidence, and Aidoc is a close second on clearance breadth. Every entry follows the same structure, uses the same evidence-tier labels and includes a “Why #N” line that ties its rank to its scores.

1. Viz.ai (Viz.ai One): Best for Stroke Detection and Care Coordination

Category: Detect-and-Coordinate. AI that flags suspected time-critical imaging findings and coordinates the care team’s response.

At a Glance

• Category: Detect-and-Coordinate
• Best For: Comprehensive and thrombectomy-capable stroke centers running hub-and-spoke transfer networks
• Price Range: Pricing on request; Viz.ai reports CMS NTAP history, which is a hospital payment rather than a vendor price (current amount unverified as of November 2026)
• Primary Strength: Viz.ai has the strongest independent workflow evidence in this review, including a 2025 meta-analysis of 15,595 patients that linked Viz.ai use to faster door-to-groin times.
• Biggest Limitation: Viz.ai’s independent evidence shows faster process times but no significant change in length of stay, and NICE found the evidence insufficient for routine use.
• One-Line Summary: Viz.ai is a stroke-focused AI detection and care-coordination platform whose independently supported strength is faster treatment workflows, not proven reductions in hospital length of stay.
• Last Verified: November 2026

Why #1 (3.95/5): Viz.ai scored highest on independent evidence (C2 4.0), backed by a 2025 meta-analysis of Viz.ai use, and tied for top deployment (C3 5.0). Viz.ai scored below Aidoc on regulatory specificity (C1 4.0 vs. 4.5) because its 13 reported clearances are not mapped to modules.

Overview

Viz.ai One is an AI care-coordination platform for hospital stroke programs and hub-and-spoke networks. It detects suspected time-critical conditions such as large vessel occlusion (LVO) on imaging and alerts care teams on mobile devices. Viz.ai One then coordinates the team’s response through built-in messaging.

Viz.ai received the first FDA De Novo for AI computer-aided triage in February 2018, for the product then called Viz.ai Contact and now called Viz LVO [Source: FDA, 2018]. Viz.ai reports 13 FDA clearances, a total PlugRoute could not reconcile with public FDA records.

Viz.ai was founded in 2016 and reports a $100M Series D at a reported $1.2B valuation [Source: Viz.ai, accessed 2026].

Key Features

• Viz.ai analyzes CT angiography for suspected large vessel occlusion and sends alerts to stroke team members’ mobile devices.
• Viz.ai includes built-in care-team messaging so spoke and hub clinicians can discuss a flagged patient in real time.
• Viz.ai holds later clearances such as Viz CTP (CT perfusion) and Viz ICH, both cleared by 2020 [Source: Viz.ai via PR Newswire, accessed 2026].
• Viz.ai offers pathways beyond stroke, such as pulmonary embolism, and each pathway has its own regulatory status.
• Viz.ai holds the first FDA De Novo for ECG-based cardiovascular software and reported 13 life-sciences partnerships, including Medtronic, at the end of 2025 [Source: Viz.ai, 2025].

Best For

Viz.ai is best for stroke program directors in hub-and-spoke networks where coordination between spoke and hub hospitals is the bottleneck. Viz.ai is a weaker fit for standalone hospitals without a transfer network, where the coordination layer has less to coordinate.

Strengths

• Viz.ai use was associated with shorter door-to-groin puncture and door-in-door-out times in a 2025 meta-analysis of 12 studies and 15,595 patients [Source: Translational Stroke Research, 2025].
• Viz.ai was associated with an 86.7-minute reduction in door-in-to-groin-puncture time for transferred LVO patients (206.6 to 119.9 minutes, p<0.0001) in a single-network pre/post study [Source: Hassan et al., hosted by Viz.ai, accessed 2026].
• Viz.ai was linked to faster neurointerventional notification in the VALIDATE study of 14,116 cases [Source: Viz.ai publications, accessed 2026].
• Viz.ai holds a 4.3/5 G2 rating from 29 reviews [Source: G2, 2026].
• Viz.ai’s coordination value is illustrated by one radiologist who said LVO alerts trigger stroke-team chat that gives “awesome history and extra sets of eyes.” That is one practitioner’s account, not a representative sample [Source: r/radiologyAI, 2026].

Limitations

Viz.ai’s most consequential trade-off is that its proven benefit is speed, not outcomes. The 2025 meta-analysis found no significant change in hospital length of stay with Viz.ai use [Source: Translational Stroke Research, 2025].

• Viz.ai was among the stroke AI tools that NICE, in its consultation recommendations, judged to have insufficient evidence for routine use. NICE could not determine their cost-effectiveness [Source: NICE consultation, accessed 2026].
• Viz.ai and other stroke AI platforms showed variable performance on distal/medium-vessel and posterior-circulation occlusions in a scoping review [Source: scoping review, accessed 2026].
• Viz.ai’s marketing cites a head-to-head study claiming higher specificity and PPV than a competitor, but that comparison is a vendor summary [Source: Viz.ai, accessed 2026].

Verdict

Viz.ai is the best-evidenced AI platform in this review for speeding stroke treatment workflows in hub-and-spoke networks, although independent evidence has not shown that it shortens hospital stays.

Stroke centers considering Viz.ai should run a local head-to-head against RapidAI or Brainomix and test distal and posterior-circulation cases specifically. Buyers should also confirm the FDA record for each Viz.ai module before signing.

For comparison, a CT technologist on r/RadiologyCareers described the competing RapidAI workflow:

“We use RAPID for our stroke protocols. They render our Perfusions/CTA Head/Neck and AI picks up occlusions, infarcts, hemorrhages, etc. It’s crazy how precise it is but at the end of the day the Radiologist dictates and finalizes the AI read since there can be incidents AI can misread especially if a patient moves during the scan. I’m not sure which 3rd party program your facility uses but RAPID is efficient enough our neuro team relies on the AI program.” Posted by u/biggie_notsosmall

Takeaway: Frontline teams trust RapidAI, Viz.ai’s most direct head-to-head rival, for stroke-protocol precision, but radiologists still finalize every read because patient motion can cause AI misreads.

2. Aidoc (aiOS + CARE): Best for Enterprise Imaging AI Orchestration

Category: Orchestrator. An enterprise layer that sends imaging exams to multiple AI models and governs them in one workflow.

At a Glance

• Category: Orchestrator
• Best For: Health systems that want many acute-imaging AI algorithms, including third-party models, under one governance layer
• Price Range: Pricing on request (enterprise quote; per-study vs. fixed licensing not disclosed)
• Primary Strength: Aidoc aiOS combines one of the broadest acute-imaging clearance portfolios in this review with the ability to orchestrate partner and homegrown algorithms.
• Biggest Limitation: Aidoc’s turnaround and length-of-stay results are vendor-reported without published methods, and Aidoc’s own pages list conflicting clearance counts.
• One-Line Summary: Aidoc is an enterprise imaging AI orchestration platform with the broadest explicitly listed acute-imaging clearances in this review, but most of its outcome claims still await independent validation.
• Last Verified: November 2026

Why #2 (3.83/5): Aidoc had the highest regulatory-scope score (C1 4.5) and tied for top deployment (C3 5.0). Aidoc trails Viz.ai by 0.12 because its outcome figures are vendor-reported without published methods (C2 3.0).

Overview

Aidoc aiOS is an enterprise clinical AI layer for health systems that want many imaging AI tools on one platform. It routes exams to Aidoc-built, partner and homegrown algorithms and shows findings inside radiology workflows. Aidoc aiOS also monitors model performance after deployment.

Aidoc’s CARE foundation model adds multi-indication CT triage. Aidoc says 69% of its customers run partner or homegrown algorithms on aiOS [Source: Aidoc, 2026], so buyers must confirm exactly which algorithms a deployment includes.

Aidoc was founded in 2016. On April 29, 2026, Aidoc announced a $150 million Series E led by Goldman Sachs Alternatives [Source: Aidoc, 2026].

Key Features

• Aidoc aiOS routes each imaging exam to the relevant AI models and shows findings in the radiologist’s PACS worklist and clinical workflow.
• Aidoc aiOS hosts third-party and homegrown algorithms alongside Aidoc’s own models.
• Aidoc’s CARE abdominal CT triage product was cleared by FDA in January 2026 and covers 14 indications, including aortic dissection and appendicitis [Source: Aidoc, 2026].
• Aidoc provides algorithm monitoring and governance tools for tracking model performance after deployment.
• Aidoc’s legacy portfolio covers acute findings such as pulmonary embolism, intracranial hemorrhage and C-spine fracture.

Best For

Aidoc is best for health system CIOs, CMIOs and radiology chairs who want one enterprise contract and governance layer for multiple acute-imaging algorithms. Aidoc is a weaker fit for small practices doing routine, already-efficient reads, where per-study AI costs can exceed the savings.

Strengths

• Aidoc’s CARE abdominal CT pivotal study reported mean sensitivity of 97% and mean specificity of 98% across 11 newly cleared indications. Those are pivotal regulatory results, not routine-deployment results [Source: Aidoc, 2026].
• Aidoc’s orchestration model is supported by a US private-practice radiologist who runs Gleamer fracture detection alongside Aidoc’s ICH and PE modules on the same platform [Source: r/radiologyAI, 2026].
• Aidoc received FDA Breakthrough Device designation for its multi-condition platform. The designation speeds FDA review but does not itself authorize clinical use [Source: Applied Radiology, accessed 2026].
• Aidoc reports more than 1,600 deployed sites, a vendor-reported figure that varies across Aidoc’s own pages [Source: Aidoc, 2026].
• Aidoc’s G2 reviewers rate it 4.3/5 from 19 reviews and praise its workflow efficiency and integration with hospital systems [Source: G2, 2026].

Limitations

Aidoc’s most consequential trade-off is breadth over independently proven outcomes. Aidoc’s 22–55% turnaround reductions and its length-of-stay drops come from its own solutions page, which gives no cohort or method details [Source: Aidoc, accessed 2026].

• Aidoc was among the stroke AI tools that NICE judged to have insufficient evidence for routine use [Source: NICE consultation, accessed 2026].
• Aidoc’s materials disagree on clearance counts. One page lists 17 Aidoc-developed plus 8 partner algorithms, and a Hartford HealthCare release cites 17 [Source: Aidoc, accessed 2026].
• Aidoc’s G2 reviewers say some features take time to learn and can feel slow [Source: G2, 2026].
• Aidoc’s results may vary by site. In the same thread, one radiologist said the AI tools they had used “just slow me down,” though that comment was about AI tools in general, not Aidoc specifically [Source: r/radiologyAI, 2026].

Verdict

Aidoc is the best-fit choice in this review for health systems that want one governed platform for many acute-imaging AI algorithms, as long as they verify each algorithm’s clearance and validate outcomes locally.

Aidoc’s foundation-model clearances list their indications explicitly, and practitioners confirm its third-party hosting. Aidoc’s outcome claims are still vendor-reported, so health systems should run a silent prospective pilot that measures turnaround and alert burden before system-wide rollout.

3. Qure.ai (qXR, qER, qCT): Best for Chest X-Ray, Head CT and TB Screening

Category: Imaging Point Solution. FDA-cleared AI for specific findings on specific imaging modalities.

At a Glance

• Category: Imaging Point Solution
• Best For: Radiology departments with defined chest X-ray, head CT or lung-nodule use cases, and public-health TB screening programs
• Price Range: Pricing on request (custom; per-study vs. program-level licensing not disclosed)
• Primary Strength: Qure.ai publishes product-specific FDA clearances and has independent multi-product TB evaluations, including the highest AUC in one five-system head-to-head.
• Biggest Limitation: Qure.ai’s qXR reached 48.7% specificity at 95.5% TB sensitivity. That is slightly higher than an expert human reader’s 42.2%, but it still means a heavy false-positive load for screening programs.
• One-Line Summary: Qure.ai is a chest and head imaging AI vendor with product-specific FDA clearances and independent TB-screening evidence, best suited to programs that can tune operating thresholds to their population.
• Last Verified: November 2026

Why #3 (3.53/5): Qure.ai scored well on product-level regulatory documentation (C1 4.0) and has rare independent multi-product evidence (C2 3.5). Qure.ai scored lower on US hospital deployment fit (C3 4.0) and practitioner signal (C5 3.0). Its vendor-stability score (C6 3.5) is lower because its founding date and funding could not be verified.

Overview

Qure.ai is an imaging AI vendor for radiology departments and public-health screening programs. Its qXR, qER and qCT products give FDA-cleared, task-specific analysis of chest X-rays, non-contrast head CT and lung nodules. Qure.ai is not a general diagnostic engine, and each Qure.ai product has its own intended use.

Qure.ai’s regulatory page lists 7 cleared products, while a company release claims 26 FDA-cleared indications across 9 products [Source: Qure.ai, accessed 2026].

Qure.ai is headquartered in Mumbai. Its founding date and funding were not verified in this research.

Key Features

• Qure.ai qER triages non-contrast head CT for suspected intracranial hemorrhage, mass effect, midline shift and cranial fracture.
• Qure.ai qXR variants are FDA-cleared for tasks such as breathing-tube placement, pneumothorax and lung nodules.
• Qure.ai qCT-Quant and qCT Lung measure lung nodules of 4–30 mm in the screening population.
• Qure.ai qXR is a computer-aided detection (CAD) product of the type that WHO guidance recommends for TB screening in people aged 15 and older. That recommendation covers the product category, not qXR specifically, and TB screening is not an FDA-cleared use [Source: Qure.ai, accessed 2026].
• Qure.ai holds CE Class IIb certification under EU MDR for qXR v4.0, qER-NCCT, qCT and qMSK.

Best For

Qure.ai is best for TB and lung screening programs, including active case finding in mobile and lower-resource settings, and for radiology departments that need specific chest X-ray or head CT triage. Qure.ai is a weaker fit for US hospitals that want a single multi-finding platform rather than task-specific products.

Strengths

• Qure.ai qXR had the highest AUC in an independent five-system head-to-head TB evaluation. The margin was small, and results varied across patient subgroups [Source: independent TB evaluation, accessed 2026].
• Qure.ai qXR reached 48.7% specificity at 95.5% sensitivity in an independent evaluation of 12 TB detection products. That was slightly higher than an expert human reader’s 42.2% at the same sensitivity, though the difference was not statistically significant [Source: Scientific Reports, 2021].
• Qure.ai publishes a US regulatory page that lists each cleared product and its task, so its products are easier to verify than those of vendors that publish only aggregate counts [Source: Qure.ai, accessed 2026].
• Qure.ai’s G2 reviewers rate it 4.3/5 from 24 reviews [Source: G2, 2026].

Limitations

Qure.ai’s most consequential trade-off is sensitivity against specificity. At 48.7% specificity and 95.5% sensitivity, qXR generates many false-positive referrals that programs must budget for [Source: Scientific Reports, 2021].

Here is an illustration that assumes 5% prevalence. Screening 1,000 people would flag about 48 true cases and about 487 false positives, or roughly 10 follow-ups per true case. An expert reader at the same sensitivity would produce slightly more false positives.

• Qure.ai’s US regulatory summaries lack demographic subgroup performance data, which makes local performance harder to predict [Source: Qure.ai FDA summaries, accessed 2026].
• Qure.ai’s prospective NHS evaluation has not published results, and staff raised concerns about missed subtle abnormalities [Source: MedAI Verdict profile, accessed 2026].
• Qure.ai is described as more oriented toward screening and public health than typical US private-practice offerings, and no Reddit practitioner signal was found [Source: Radiological.ai market comparison, 2026].

Commenters on r/AI_India questioned Qure.ai’s market position:

“GE has the most patent in AI healthcare, you can also check their recent partnerships with Nvidia as well as their algorithms such as automated organ segmentation, lesion detection, etc are already FDA approved. Qure.ai has been trying for many years but I don’t think this a problem worth solving in India, its better you take grant from government and build a cheaper MRI/Ultrasound machine with embedded AI in it that can be used in rural India!” Posted by u/frittaa454

Takeaway: Even in its home market, Qure.ai draws skepticism from observers who see incumbents like GE ahead on FDA-approved imaging AI and think cheaper AI-embedded scanners would matter more.

Verdict

Qure.ai is the best-documented option in this review for chest X-ray and TB screening programs that need high sensitivity and can manage the false-positive load that comes with it.

Qure.ai’s product-level clearances are easy to verify, and its independent TB results match or slightly exceed an expert reader. US hospitals should compare Qure.ai with Annalise.ai or Lunit on their own case mix and confirm each product’s FDA intended use.

4. OpenEvidence: Best Free Clinician Evidence Tool (Not an FDA-Cleared Device)

Category: Clinical Decision Support (Non-Device). Reasoning and evidence tools that assist clinicians but are not FDA-cleared diagnostic devices.

At a Glance

• Category: Clinical Decision Support (Non-Device)
• Best For: Individual clinicians who want fast, cited evidence lookup and help broadening a differential
• Price Range: Free for verified US/Canadian healthcare professionals (ad-supported, including pharma ads); no verified paid tier or API price
• Primary Strength: OpenEvidence combines free access, citation-linked answers drawn from licensed NEJM and JAMA content, and the highest review volume in this evaluation.
• Biggest Limitation: OpenEvidence is not an FDA-cleared diagnostic device, and it misapplied cited evidence in 13.3% of cases in one independent implant-dentistry evaluation.
• One-Line Summary: OpenEvidence is a free, ad-supported LLM evidence tool that clinicians widely use for differentials, but it is not an FDA-cleared diagnostic device and its cited answers still need verification.
• Last Verified: November 2026

Why #4 (3.10/5): OpenEvidence had the highest peer-signal score (C5 5.0) and strong pricing transparency (C4 4.0). It got the lowest regulatory score (C1 1.0) because it is not a cleared device. OpenEvidence edges out Isabel DDx Companion on deployment and reviews, while Isabel leads on evidence and pricing.

Overview

OpenEvidence is a free, ad-supported, LLM-based clinical question-answering tool for verified US and Canadian clinicians who want fast evidence lookup and differential support. OpenEvidence is not an FDA-cleared diagnostic device. OpenEvidence returns citation-linked answers that draw on licensed NEJM Group and JAMA Network content.

OpenEvidence came out of the Mayo Clinic Platform Accelerate program. OpenEvidence reports 757,000+ verified US physicians, a company or secondary figure that has not been audited [Source: Sacra, 2026].

OpenEvidence reportedly raised a $250M Series D at a $12B valuation in January 2026, according to secondary sources [Source: Sacra, 2026].

Key Features

• OpenEvidence answers clinical questions in natural language and links each answer to its cited sources.
• OpenEvidence has content agreements with NEJM Group and JAMA Network that give it licensed journal content.
• OpenEvidence DeepConsult, launched in July 2025, is a longer-form research mode for complex questions.
• OpenEvidence Visits adds ambient clinical documentation alongside the evidence tool.
• OpenEvidence is free for verified healthcare professionals, including on iOS, while UpToDate costs about $579/year for comparison [Source: PubMed Central review, accessed 2026].

Best For

OpenEvidence is best for individual physicians, residents and advanced practice clinicians who want a free, fast way to check evidence and widen a differential. OpenEvidence should not be used as a regulated diagnostic device, and no one should enter PHI into it before an institutional security review.

Strengths

• OpenEvidence has the strongest peer-review signal in this evaluation, with 4.9/5 from about 12,000 ratings [Source: Apple App Store, November 2026] and 4.4/5 from 44 reviews [Source: G2, 2026].
• OpenEvidence produced no fabricated citations in one independent evaluation, although it did misapply some sources [Source: independent implant-dentistry evaluation, 2026].
• OpenEvidence reports about 20 million monthly consultations as of January 2026, an unaudited company or secondary figure [Source: Sacra, 2026].
• OpenEvidence works in literature search, which a separate Doximity survey found is physicians’ top AI use at 35%. That survey is market context, not evidence about OpenEvidence [Source: Doximity via HealthExec, 2026].
• OpenEvidence’s licensed NEJM Group and JAMA Network content gives its citations a curated journal base [Source: PubMed Central review, accessed 2026].

Users on r/Residency noted:

“Never ChatGPT. And will never use it to help me direct actual patient care.

All the cool kids seem to use OpenEvidence anyways. Backed by the NEJM, free has long as you are a doctor (have an NPI) and earns you CME, apparently.

Distrust and dislike the road humanity is going down with AI, but know one day admin is going to hoist it upon us, so at least pick the one that might do less harm.” Posted by u/Strange_Return2057

Takeaway: Residents choose OpenEvidence for its NEJM backing and free NPI-based access, not out of confidence in clinical AI. Even its users treat it as the least-bad option.

Limitations

OpenEvidence’s most consequential trade-off is convenience over validation. OpenEvidence is not an FDA-cleared diagnostic device, and it misapplied cited evidence in 13.3% of cases in one independent implant-dentistry evaluation [Source: independent implant-dentistry evaluation, 2026].

• OpenEvidence’s accuracy varies widely by task in independent evaluations, so clinicians should check every answer against its sources [Source: Wiley Online Library review, accessed 2026].
• OpenEvidence’s ad-supported model includes pharma advertising, which raises conflict-of-interest questions. Buyers should weigh those against the company’s statement that advertisers cannot influence answers.
• OpenEvidence claims HIPAA compliance, but critics advise an institutional security review before anyone enters PHI [Source: Wiley Online Library review, accessed 2026].
• OpenEvidence’s G2 reviewers report shallow answers on complex queries, and App Store users report “high demand” errors [Source: G2 and Apple App Store, 2026].

Verdict

OpenEvidence reports the largest clinician user base in this review (757,000+ verified US physicians, company figure), but it is decision support, not a validated diagnostic device.

OpenEvidence works well for research and for widening a differential when users check its citations. Health systems should put OpenEvidence through a formal security and PHI review instead of allowing ad hoc adoption, and they should not treat adoption figures as diagnostic validation.

5. Isabel DDx Companion: Best Structured Differential Tool with Public Pricing

Category: Clinical Decision Support (Non-Device). Reasoning and evidence tools that assist clinicians but are not FDA-cleared diagnostic devices.

At a Glance

• Category: Clinical Decision Support (Non-Device)
• Best For: Clinicians, trainees and institutions that want a structured differential-diagnosis aid with predictable cost
• Price Range: $149/year Standard and $199/year Premium for individuals; $49/year students/residents; 30-day free trial; institutional pricing on request
• Primary Strength: Isabel DDx Companion pairs a non-LLM engine covering 10,000+ conditions with fully public pricing and a 30-day free trial.
• Biggest Limitation: Isabel DDx Companion’s 95–96% accuracy claim means the right diagnosis appears somewhere in its list. A 2025 independent rare-disease study found a top-ten rate of only 28%.
• One-Line Summary: Isabel DDx Companion is a structured, non-LLM differential-diagnosis engine with fully public pricing. It is best used to widen a differential and catch “don’t miss” diagnoses rather than to pick a single answer.
• Last Verified: November 2026

Why #5 (2.90/5): Isabel DDx Companion had the top pricing-transparency score (C4 5.0) and solid education evidence (C2 3.5). Isabel DDx Companion scored low on peer signals (C5 1.5) because it has no verified review-platform presence. It also scored low on regulatory scope (C1 1.5) as a non-device tool.

Overview

Isabel DDx Companion is a non-LLM differential-diagnosis engine for clinicians, trainees and institutions. It matches entered clinical features against a curated database of 10,000+ conditions and flags “don’t miss” diagnoses. Isabel DDx Companion is not an FDA-cleared diagnostic device.

Isabel DDx Companion can run standalone or with an EHR integration, and it is distributed through EBSCO.

Isabel Healthcare reports 20+ years of use in 90+ countries [Source: Isabel Healthcare, accessed 2026], although its founding year was not verified.

Key Features

• Isabel DDx Companion accepts clinical features as free text or through autocomplete, including labs, imaging findings and risk factors.
• Isabel DDx Companion builds its differential with a curated, non-LLM matching engine that covers all ages and specialties.
• Isabel DDx Companion flags “don’t miss” diagnoses so dangerous conditions stand out in the list.
• Isabel DDx Companion Premium adds an LLM layer that compares and summarizes diagnoses, while the core engine still produces the list.
• Isabel DDx Companion prices institutional plans by admissions or users and includes setup, training, support and “basic integrations” [Source: Isabel Healthcare, accessed 2026].

Best For

Isabel DDx Companion is best for clinicians and medical educators who want a knowledge-base differential designed to return consistent lists for the same inputs, and for institutions that need predictable pricing. Isabel DDx Companion fits less well where clinicians want conversational, unstructured case summaries.

Strengths

• Isabel DDx Companion is the only product in this evaluation with fully public individual pricing ($149–$199/year) and a 30-day free trial [Source: Isabel Healthcare, accessed 2026].
• Isabel DDx Companion reports that the correct diagnosis appears in its top-ten differential in 95–96% of cases, based on accuracy studies listed on its validation pages [Source: Isabel Healthcare, accessed 2026].
• Isabel DDx Companion is cited in randomized trials at medical schools, listed by Isabel Healthcare, that showed clinical-reasoning skills improving by up to 33% [Source: Isabel Healthcare, accessed 2026].
• Isabel DDx Companion’s Pro engine was found to complement ChatGPT-4 in a comparison study listed by Isabel Healthcare [Source: Isabel Healthcare, accessed 2026].

Limitations

Isabel DDx Companion’s most consequential trade-off is breadth over precision. Its 95–96% figure means the correct diagnosis appears somewhere in a list of about ten, not that the top suggestion is right.

• Isabel DDx Companion listed at least one confirmed diagnosis in its top ten for only 28% of patients in a 2025 independent study of 100 rare-disease cases, which shows that accuracy depends on case mix [Source: Orphanet Journal of Rare Diseases, 2025].
• Isabel DDx Companion has no verified G2, Capterra or App Store reviews, and its accuracy studies are curated on its own site.
• Isabel DDx Companion’s specific Epic or Cerner integrations were not verified. In one Reddit thread asking for differential-diagnosis tools, the only tool anyone named was OpenEvidence [Source: r/therapists, 2026].
• Isabel DDx Companion may handle unstructured context less well than LLM tools, according to competitor Glass Health, which is a biased source [Source: Glass Health, accessed 2026].

Verdict

Isabel DDx Companion is the most transparently priced differential-diagnosis aid in this evaluation, and it is best used to widen a differential rather than to name the answer.

Isabel DDx Companion’s non-LLM engine is designed to return consistent lists for the same inputs, which suits trainees and institutions. Clinicians should read its accuracy claims as “in the list,” and institutions should confirm the exact EHR integration before purchase.

6. PathAI (AISight Dx): Best Digital Pathology Platform for Labs Going Digital

Category: Pathology Platform and AI. Whole-slide image viewing and management plus pathology AI algorithms.

At a Glance

• Category: Pathology Platform and AI
• Best For: Anatomic pathology labs digitizing their whole-slide workflow that want a cleared viewer able to host multiple AI apps
• Price Range: Pricing on request, plus scanner, storage, LIS integration and validation costs; no self-serve trial
• Primary Strength: PathAI AISight Dx holds a verified 2025 FDA 510(k) for primary-diagnosis image viewing and management and can host third-party pathology apps.
• Biggest Limitation: PathAI’s key clinical AI algorithms, including AIM-PD-L1 and AIM-HER2, are Research Use Only in the US, so the cleared platform does not mean the AI is cleared.
• One-Line Summary: PathAI AISight Dx is an FDA-cleared digital pathology viewing and management platform, but most PathAI AI algorithms remain Research Use Only in the US.
• Last Verified: November 2026

Why #6 (2.55/5): PathAI AISight Dx has a verified 2025 510(k) (C1 3.0), but its key algorithms are Research Use Only. No independent performance evidence was found (C2 2.0), and pricing is quote-only with added digitization costs (C4 1.5). Those gaps place PathAI below the decision-support tools.

Overview

PathAI AISight Dx is an FDA-cleared digital pathology image viewing and management platform for primary diagnosis. It is built for anatomic pathology labs that have digitized, or plan to digitize, their whole-slide imaging (WSI) workflow. PathAI AISight Dx can host PathAI and third-party pathology apps.

Each PathAI AI algorithm has its own regulatory status, and most are Research Use Only.

PathAI was founded in 2016. In 2024, Quest Diagnostics bought PathAI’s clinical lab assets and licensed AISight [Source: Quest Diagnostics, 2024].

Key Features

• PathAI AISight Dx provides whole-slide image viewing and case management under FDA 510(k) K243391, with a decision date of June 26, 2025 [Source: FDA, 2025].
• PathAI AISight Dx can host third-party pathology AI apps, including Paige’s, inside one viewer.
• PathAI AISight Dx is cleared only with specific scanner configurations, such as the Roche VENTANA DP200/DP600.
• PathAI offers AIM-PD-L1, AIM-HER2 and a breast biomarker panel, and all three are Research Use Only in the US.
• PathAI’s AIM-MASH algorithm holds FDA and EMA Drug Development Tool qualification (2025) for drug-trial use, which is not a diagnostic clearance.

Best For

PathAI AISight Dx is best for pathology department heads and lab directors who are building a digital pathology foundation and want a cleared viewer that can host AI from several vendors. PathAI AISight Dx is a poor fit for labs that need cleared diagnostic AI algorithms now rather than a cleared viewer.

Strengths

• PathAI AISight Dx received FDA 510(k) K243391 on June 26, 2025, as a digital pathology image viewing and management system for primary diagnosis. PlugRoute verified this in the primary FDA record [Source: FDA, 2025].
• PathAI AISight Dx can host third-party apps, including Paige’s, which reduces lock-in to one AI vendor’s viewer [Source: AI Health Index, accessed 2026].
• PathAI’s G2 reviewers (36 reviews) praise its ease of use and efficient workflows [Source: G2, 2026].
• PathAI’s AIM-MASH earned FDA and EMA Drug Development Tool qualification in 2025, which supports its use in drug development but not in diagnosis [Source: PathAI, 2025].

Limitations

PathAI’s most consequential trade-off is that its cleared product is the platform, not the AI. AIM-PD-L1, AIM-HER2 and the breast biomarker panel are Research Use Only in the US, so buyers must verify each algorithm separately.

• PathAI’s adoption figures, including 26 clinical trials and “90% of top 15 biopharma,” are vendor-reported. No published performance study of AISight Dx was found beyond the 510(k) record [Source: PathAI, accessed 2026].
• PathAI AISight Dx deployment depends on cleared scanners and full digitization, which third-party reviews flag as hurdles [Source: AI with Kay, accessed 2026].
• PathAI’s G2 users report a learning curve on advanced features [Source: G2, 2026].
• PathAI’s 2024 sale of its clinical lab assets to Quest Diagnostics shifted its clinical footprint toward licensing [Source: Quest Diagnostics, 2024].

Verdict

PathAI AISight Dx is a credible, FDA-cleared foundation for digital pathology workflows, but labs should not read that platform clearance as clearance for diagnostic AI.

PathAI AISight Dx’s third-party hosting reduces vendor lock-in. PathAI’s algorithms are mostly Research Use Only and its performance evidence is vendor-reported, so labs should budget for digitization and validate each AI application separately.

7. Paige (Tempus): Best Prostate Biopsy AI Adjunct for Digitized Labs

Category: Pathology Platform and AI. Whole-slide image viewing and management plus pathology AI algorithms.

At a Glance

• Category: Pathology Platform and AI
• Best For: Digitized anatomic pathology labs with meaningful prostate needle-biopsy volume
• Price Range: Pricing on request (not public), plus scanner, storage and validation costs
• Primary Strength: Paige Prostate Detect holds the first FDA De Novo authorization for AI pathology software, verified in the primary FDA record.
• Biggest Limitation: Paige Prostate Detect’s authorized indication is narrow. It is an adjunct that flags one likely cancer location on prostate biopsies after the pathologist’s own review.
• One-Line Summary: Paige Prostate Detect is the first FDA-authorized AI pathology product, but its clearance covers only a narrow prostate-biopsy adjunct use, and Paige is now part of Tempus.
• Last Verified: November 2026

Why #7 (2.23/5): Paige has a De Novo verified in the primary FDA record (C1 3.5), but the study figures circulating for it are unverified (C2 2.0). Paige also has no verified reviews because of a name collision (C5 1.0), it does not disclose pricing (C4 1.0), and its ownership changed in 2025 (C6 2.5).

Overview

Paige Prostate Detect, now offered by Tempus, is the first FDA-authorized AI pathology software. It is an adjunct for digitized labs with prostate biopsy volume that flags the single area most likely to contain cancer after the pathologist’s review. Paige Prostate Detect works on H&E prostate needle-biopsy whole-slide images.

Paige Prostate Detect received FDA De Novo DEN200080 on September 21, 2021, which PlugRoute verified in the primary FDA record [Source: FDA, 2021]. Paige’s other products, including PanCancer Detect and Paige Predict, are not FDA-cleared.

Paige was founded in 2017, and Tempus announced its acquisition of Paige on August 22, 2025 [Source: Tempus, 2025].

Key Features

• Paige Prostate Detect flags the single location most likely to be cancer on H&E prostate needle-biopsy whole-slide images, after the pathologist’s initial review.
• Paige FullFocus is a whole-slide viewer listed as cleared with Philips, Leica Aperio GT 450 DX and Hamamatsu S360MD scanners.
• Paige Prostate received EU IVDR certification in 2025 for European clinical use.
• Paige’s Virchow foundation model was trained on 1.5 million H&E whole-slide images drawn from an archive of nearly 7 million slides.
• Paige PanCancer Detect received FDA Breakthrough Device designation in 2025, which does not authorize clinical use.

Best For

Paige Prostate Detect is best for pathology labs that already run a digital whole-slide workflow on a cleared scanner and want a regulator-authorized second look on prostate biopsies. Paige is a poor fit for labs that want broad, multi-tissue cleared diagnostic AI.

Strengths

• Paige Prostate Detect received FDA De Novo DEN200080 on September 21, 2021. It was the first FDA authorization for AI pathology software, and PlugRoute verified it in the primary FDA record [Source: FDA, 2021].
• Paige FullFocus is now listed as cleared with three scanner vendors, wider than its original Philips-only authorization [Source: Tempus, accessed 2026].
• Paige Prostate earned EU IVDR certification in 2025, a separate European authorization [Source: Tempus, accessed 2026].
• Paige’s Virchow foundation model was trained on 1.5 million H&E whole-slide images from 45 countries [Source: Tempus, accessed 2026].

Limitations

Paige’s most consequential trade-off is a first-of-its-kind but narrow authorization. Paige Prostate Detect is cleared only as an adjunct that flags one location on prostate needle biopsies after the pathologist’s review.

• Paige PanCancer Detect holds only a 2025 Breakthrough designation, and Paige Predict (NSCLC, melanoma, endometrial) is positioned for research use [Source: Tempus, accessed 2026].
• Paige study figures that circulate, such as a 70% reduction in false negatives, could not be verified, so buyers should ask for the peer-reviewed publications.
• Paige has no verified review-platform presence because the $99 and $39 “Paige” listings on G2 and Capterra belong to an unrelated local-SEO product.
• Paige was acquired by Tempus for $81.25 million, mostly in stock, and Tempus also took on Paige’s Microsoft Azure commitment. Paige’s roadmap now depends on Tempus, although no product discontinuations have been documented [Source: Tempus, 2025].

Verdict

Paige Prostate Detect is a regulator-authorized but clinically narrow AI adjunct for prostate biopsy review, and it is strongest for labs that are already digital.

Paige’s first-ever De Novo and multi-scanner clearance can be verified. Paige’s performance figures are unverified, it has no reviews and its roadmap has changed since the acquisition. Buyers should confirm Tempus’s support commitments and ask for published evidence before contracting.

Also Considered: Not Ranked

AI answer engines named several products that were not researched to the same standard as the seven ranked entries. To keep equal depth for every ranked product, PlugRoute lists these by category without ranking them. Buyers should run the same regulatory and evidence checks on each one before adding it to a shortlist.

• RapidAI (Detect-and-Coordinate): RapidAI reported a 2026 expansion to all 18 OSF hospitals (vendor-reported), was included in NICE’s insufficient-evidence assessment, and is the natural head-to-head comparator for Viz.ai.
• Brainomix (Detect-and-Coordinate): Brainomix was included in NICE’s stroke AI assessment.
• Annalise.ai (Imaging Point Solution): Annalise.ai describes a 12-finding US chest X-ray and head CT triage package, which buyers should check against FDA records.
• Lunit (Imaging Point Solution): Lunit offers chest X-ray and mammography AI and is listed as a Qure.ai competitor.
• ScreenPoint Medical (Imaging Point Solution): ScreenPoint Medical focuses on breast imaging and was not researched in depth.
• DeepHealth (Imaging Point Solution): DeepHealth announced an FDA 510(k) for breast ultrasound in July 2026 (company announcement).
• Glass Health (Clinical Decision Support): Glass Health is an LLM differential tool whose benchmark claims are vendor-reported.
• VisualDx (Clinical Decision Support): VisualDx offers visual-comparison decision support and states that it does not itself diagnose.
• DxGPT (Clinical Decision Support): DxGPT was named by an answer engine but not researched.
• Ada Health and Ubie (Consumer Symptom Checkers): Ada Health and Ubie are covered only in the consumer safety section below, and Ada states that it cannot diagnose.

What Does FDA Clearance Actually Cover for AI Diagnostic Tools?

FDA clearance covers one specific device for its listed indications, in a specific version and sometimes with a specific hardware setup. FDA clearance never covers a whole company or platform. Several other labels are often mistaken for clearance, so buyers should check the FDA record number for every algorithm they buy.

FDA clears a device, an indication and a version. FDA does not clear a company, a platform or a press release.

The ranked products include these documented cases of scope confusion:

• Aggregate counts: Aidoc’s own pages list 17 algorithms in one place and 17 Aidoc-developed plus 8 partner algorithms in another, and Viz.ai’s reported 13 clearances could not be reconciled with public FDA records.
• Counting method: Qure.ai lists 7 cleared products on its regulatory page but claims 26 indications across 9 products in a release.
• Platform vs. algorithm: PathAI AISight Dx is cleared as a viewer, while PathAI’s AIM-PD-L1 and AIM-HER2 are Research Use Only.
• Qualification vs. clearance: PathAI AIM-MASH holds Drug Development Tool qualification, which applies to drug trials, not diagnosis.
• Designation vs. clearance: Paige PanCancer Detect and Aidoc’s multi-condition platform hold Breakthrough designations, which are not authorizations.
• Category recommendation vs. clearance: WHO guidance recommends TB CAD software as a category, which is neither a product-specific endorsement of Qure.ai qXR nor an FDA clearance.
• Non-device tools: OpenEvidence and Isabel DDx Companion hold no FDA diagnostic authorization.

Even the regulator’s device list gives different totals depending on how it is counted. Stanford HAI counts 1,357 authorized AI/ML devices through December 2025 [Source: Stanford HAI, 2026], while Becker’s counts 1,430 authorization records [Source: Becker’s Hospital Review, accessed 2026]. Both place about three-quarters in radiology, so a vendor’s “50+ cleared algorithms” needs record numbers before anyone can check it.

Clearance also does not show how well a device performs in practice. A JAMA Network Open review of 903 FDA AI devices found clinical performance studies for only about half of them, and only 2% were randomized [Source: JAMA Network Open, accessed 2026].

Can Consumer Symptom Checkers Be Trusted?

Consumer symptom checkers should be treated as information aids, not as a diagnosis. In a BMJ study of 23 symptom checkers, the correct diagnosis was listed first only 34% of the time, and triage advice was appropriate only 57% of the time [Source: BMJ, 2015]. Anyone with concerning symptoms should seek care regardless.

The BMJ study found that triage accuracy varied by urgency [Source: BMJ, 2015]:

• Symptom checkers gave appropriate advice in 80% of emergency cases.
• Symptom checkers gave appropriate advice in 55% of non-emergency cases.
• Symptom checkers gave appropriate advice in only 33% of self-care cases.

A BMJ Open systematic review found wide variation between checkers and noted that some of Babylon’s favorable results came from evaluations run by the developer [Source: BMJ Open, 2019]. The most-cited multi-checker study in this research dates from 2015, so newer tools may perform differently.

Isabel Healthcare also offers a consumer symptom checker, but no independent triage-safety study of it was found. Ada Health states that it cannot diagnose, and PlugRoute does not rank consumer symptom checkers.

What Red Flags Should I Watch For When Evaluating AI Medical Diagnostic Platforms?

The most important red flags are regulatory claims that can’t be traced to an FDA record and outcome or cost claims that can’t be checked. Each red flag below comes from a pattern documented in this review, and each one gives procurement teams a specific claim to verify before signing.

As one user on r/PACSAdmin described:

“Hip v. Hype definitely an area of concern when non-technical person starts making buying decisions that impact technical teams solely from the sales patch. Marketing team like to pin buzz words even if they are not 100% accurate. There has always been a running joke that RSNA = Real Software Not Available, you see it but it is never available in to use in your practice.” Posted by u/Worldly-Coat-105

Takeaway: Buyers of AI diagnostic platforms face a long-running gap between marketing language and deployable software, which is why every vendor claim needs a verifiable record before procurement.

Red Flag #1: Aggregate Clearance Counts Without Record Numbers A headline count such as “50+ FDA-cleared algorithms” is hard to verify without a 510(k) or De Novo number for each item. In this review, Aidoc’s and Qure.ai’s counts differed across their own materials, and Viz.ai’s reported 13 clearances could not be reconciled with public FDA records.

Red Flag #2: Platform Clearances and Designations Marketed as Algorithm Clearances A cleared platform or an FDA program designation does not authorize the specific algorithms a vendor markets for US diagnostic use. In this review, PathAI AISight Dx is cleared but PathAI’s AIM-PD-L1 is Research Use Only, and Paige PanCancer Detect holds only a Breakthrough designation. Buyers should ask for each authorization record.

Red Flag #3: Outcome Claims With No Published Methods Turnaround or length-of-stay percentages without cohorts, comparators or methods are Tier 3 evidence and should not drive procurement on their own. In this review, independent evidence was usually more modest than vendor-reported figures. Qure.ai’s TB results, where qXR matched or slightly exceeded an expert reader, were a partial exception.

Red Flag #4: Process-Time Gains Presented as Patient Outcomes Faster notification and door-to-groin times are process gains, not proof of better patient outcomes. A 2025 meta-analysis linked Viz.ai use to faster workflow times but found no significant change in length of stay [Source: Translational Stroke Research, 2025]. Stroke AI has been shown to save minutes, not hospital days.

Red Flag #5: Per-Study Licensing on Already-Efficient Reads Per-study AI pricing can add cost without saving time on routine reads that are already efficient. Radiologists in a 2026 r/radiologyAI thread said the license model can decide whether any ROI exists at all. That is practitioner opinion, not a cost study [Source: r/radiologyAI, 2026].

Red Flag #6: Free Tools Adopted Without PHI Review Free, ad-supported clinical AI tools can spread across a health system before anyone reviews how they handle patient data. Health systems should complete a security review before clinicians enter patient information, even when the vendor claims HIPAA compliance or other self-reported certifications.

What Questions Should I Ask Before Choosing an AI Medical Diagnostic Platform?

Before choosing an AI diagnostic platform, buyers should confirm the exact FDA record for every algorithm and the independent evidence behind it. Each of the seven questions below targets a procurement risk documented in this review, from deployment scope to data security, and each one comes with guidance on what a strong vendor answer looks like.

Question #1: What is the 510(k) or De Novo number, indication and version for every algorithm in this contract? A strong answer is a written list that maps each algorithm to its FDA record number, cleared indication and version. Buyers should be cautious if a vendor answers with only an aggregate clearance count, because counts in this review conflicted even within a single vendor’s materials.

Question #2: Which third-party or homegrown algorithms are actually included in this deployment? Orchestration platforms can host models from several vendors, and each hosted model may carry its own regulatory status and fees. Buyers should ask for a line-item list that shows which algorithms are included and which ones cost extra.

Question #3: What independent, peer-reviewed evidence exists, and on what population? The strongest answers cite Tier 1 evidence, meaning independent meta-analyses or health technology assessments, rather than vendor case studies. Buyers should also ask whether the study populations resemble their own patients and scanners, since regulatory summaries often lack subgroup data.

Question #4: How will we validate performance on our own patients before go-live? Buyers should plan staged local validation. A 2024 Nature Medicine study found significant shifts in imaging data across sites and demographic groups, and showed that fairness can degrade in new settings [Source: Nature Medicine, 2024]. A practical sequence is retrospective testing, then a silent prospective pilot, then live use.

This aligns with community sentiment on r/AI_India:

“This is a poor analogy since chess has clear win/lose scenarios and rigid rules. Radiology isn’t a multiple choice exam with a correct and incorrect answer, it’s a lot more subjective than people think. Findings frequently don’t point to a single diagnosis and there’s a spectrum of overcalling and undercalling that varies by person. Validating accuracy for autonomous AI is several orders of magnitude more complicated than doing it for a game” Posted by u/mathers33

Takeaway: Validating radiology AI is harder than headline accuracy scores suggest, because reads are subjective and findings rarely map to one correct answer.

Question #5: Is licensing per-study, per-module or fixed, and what integration costs are excluded? Buyers should ask for the full cost of ownership, because the licensing model and integration work can decide whether a deployment pays off. A complete quote should itemize these cost lines:

• The quote should state whether licensing is per-study, per-module or a fixed fee.
• The quote should cover PACS, EHR and radiologist worklist integration costs.
• A pathology quote should include whole-slide scanners, image storage, LIS integration and lab validation.
• The quote should show any separate license fees for hosted third-party algorithms.

Question #6: Has this device had any recalls? Buyers should ask vendors to disclose recall history for the specific device versions in the contract. A JAMA Health Forum study found that 60 of 950 cleared AI devices had recalls, and 43% of recall events happened within a year of clearance [Source: JAMA Health Forum, accessed 2026].

Question #7: How is patient data stored, used and secured? Buyers should check how a vendor handles PHI through their institution’s own security review instead of relying on self-reported compliance claims. The vendor should answer these questions in writing:

• Where does the vendor process and store PHI?
• Does the vendor use patient data to train or improve its models?
• Which security certifications can the vendor back with independent records?

How Did We Rank These AI Medical Diagnostic Platforms?

PlugRoute scored all seven platforms from 1 to 5 on six published criteria with fixed weights, and regulatory scope and independent evidence together make up half of the total. Every score is tied to a dated, named source and an evidence tier. Rank equals weighted score, and research was completed in November 2026.

Ranking criteria and weights:

• C1 Verified Regulatory Scope (25%): Regulatory scope matters because clearance applies only to specific devices and indications. Non-device tools score low on this criterion by design.
• C2 Independent Evidence Quality (25%): Independent evidence matters because it predicts real-world results better than vendor benchmarks do.
• C3 Real-World Deployment and Integration (20%): Deployment matters because PACS, EHR and workflow integration decide whether a tool works outside a pilot.
• C4 Pricing and Licensing Transparency (10%): Pricing transparency matters because buyers need to judge total cost before procurement.
• C5 Peer Review and Practitioner Signals (10%): Peer signals matter because reviews reveal learning curves, though every G2 review count in this guide is under 50.
• C6 Vendor Stability and Ownership (10%): Vendor stability matters because acquisitions and asset sales affect roadmap and contract risk.

Evidence tiers:

• Tier 1 covers independent meta-analyses, multi-product head-to-heads and health technology assessments such as NICE.
• Tier 2 covers peer-reviewed single-site studies and pivotal regulatory studies.
• Tier 3 covers vendor-reported figures with no published methods.

Rank	Company	C1	C2	C3	C4	C5	C6	Weighted Total
1	Viz.ai	4.0	4.0	5.0	2.0	3.5	4.0	3.95
2	Aidoc	4.5	3.0	5.0	2.0	3.0	4.5	3.83
3	Qure.ai	4.0	3.5	4.0	2.0	3.0	3.5	3.53
4	OpenEvidence	1.0	3.0	4.0	4.0	5.0	4.0	3.10
5	Isabel DDx Companion	1.5	3.5	3.0	5.0	1.5	4.0	2.90
6	PathAI (AISight Dx)	3.0	2.0	3.0	1.5	2.5	3.0	2.55
7	Paige (Tempus)	3.5	2.0	2.0	1.0	1.0	2.5	2.23

The margins between #1 and #2 (0.12) and between #4 and #5 (0.20) are narrow. A high rank means the strongest verifiable evidence across all criteria, not the best tool for every reader. Readers with a specific clinical job should go by category and “Best For.”

OpenEvidence’s C1 score of 1.0 reflects that it is not a cleared diagnostic device. OpenEvidence’s #4 placement comes from its review volume, its adoption and its free model.

Items we could not verify:

• Paige’s circulating study figures and its De Novo pivotal study data were not verified for this edition.
• Viz.ai’s mapping of its 13 clearances to product modules could not be verified.
• A seven-country qXR evaluation listed by Qure.ai could not be confirmed and was not used.
• Isabel DDx Companion’s Epic or Cerner integrations, KLAS ratings for any product, PathAI’s Reddit sentiment and current NTAP amounts could not be verified.
• Publication years for several sources could not be confirmed, so those sources are cited as “accessed 2026.” They include Hassan et al., VALIDATE, the NICE consultation and the JAMA studies.

Scope and updates:

• PlugRoute researched seven vendors in depth, and products not researched to the same standard appear in “Also Considered, Not Ranked.”
• PlugRoute re-checked Qure.ai’s C2 score after adding the expert-reader comparator, and the score stayed at 3.5.
• PlugRoute re-verifies regulatory records and scores when new clearances or independent studies are published, and records any score changes in this section.

PlugRoute has no affiliate relationships with any company listed, and rankings are determined entirely by research data and objective evaluation criteria.

What Do Buyers Most Often Ask About AI Diagnostic Platforms?

Buyers most often ask which platform suits a hospital, what these platforms cost and how PlugRoute sets its rankings. In short, hospitals should choose by clinical job, most platforms are quote-only, and PlugRoute ranks by weighted, evidence-tiered criteria that it publishes in full.

What is the best AI medical diagnostic platform for hospitals in 2026?

The best AI medical diagnostic platform for a hospital in 2026 depends on its clinical job. Viz.ai leads for stroke networks, Aidoc for running many imaging algorithms under one governance layer, and Qure.ai for chest X-ray and TB screening. Hospitals should verify each algorithm’s FDA record and validate performance on local patients before rollout.

How much do AI medical diagnostic platforms cost?

Most imaging and pathology AI platforms are quote-only. Isabel DDx Companion is the only product here with public pricing ($149–$199/year for individuals), and OpenEvidence is free and ad-supported. Buyers should ask whether licensing is per-study or fixed, and pathology buyers should add scanner, storage and validation costs. Hospital NTAP payments are not vendor prices.

How does PlugRoute determine rankings?

PlugRoute determines rankings by scoring each product from 1 to 5 on six weighted criteria, led by regulatory scope and independent evidence at 25% each. Each score is tied to a dated source and an evidence tier, from independent meta-analyses down to vendor-reported figures. The rank equals the weighted total, and PlugRoute publishes the full score table.

What Do Key AI Medical Diagnostic Terms Mean?

AI diagnostic procurement uses regulatory, statistical and licensing terms that are easy to confuse, and small differences in wording can mean very different levels of authorization. The definitions below explain the terms used in this guide in plain language, so buyers can read vendor claims with the right scope in mind.

510(k) Clearance: A 510(k) clearance is an FDA decision that a device is substantially equivalent to a device already on the market. A 510(k) clearance applies only to the specific device, indication and version in the record, so buyers should match the record to the exact product they are buying.

De Novo Authorization: A De Novo authorization is an FDA pathway for new types of low-to-moderate-risk devices that have no existing equivalent. A De Novo often creates a new device category, which matters because vendors’ “first” claims usually refer to this pathway.

Indication for Use: An indication for use is the specific clinical purpose, population and setting a device is authorized for. Buyers should check that their intended use matches the indication exactly, because uses outside it are not covered by the authorization.

Research Use Only (RUO): Research Use Only means a product is not authorized for clinical diagnosis in the US. RUO tools can support research, but buyers should not let them drive patient care decisions.

Breakthrough Device Designation: A Breakthrough Device designation is an FDA program that speeds review of promising devices. A Breakthrough designation is not an authorization to market or clinically use the device, so buyers should not treat it as a clearance.

Computer-Aided Triage: Computer-aided triage software flags suspected findings so that urgent cases move up a reading queue. Computer-aided triage prioritizes cases for review and does not replace the clinician’s diagnosis, which affects how buyers should measure its value.

Computer-Aided Detection (CAD): CAD software marks or scores suspected abnormalities on an image to support a human reader. A guideline that recommends CAD as a category does not endorse any single product, so buyers still need evidence at the product level.

Sensitivity and Specificity: Sensitivity is the share of true cases a tool detects, and specificity is the share of negative cases it correctly clears. Raising one usually lowers the other, and that trade-off sets a program’s false-positive workload.

Area Under the Curve (AUC): AUC summarizes how well a model separates positive from negative cases across all thresholds. A higher AUC does not show how the model performs at the operating threshold a site actually uses, so buyers should ask for threshold-specific results.

Distribution Shift: Distribution shift happens when local patients, scanners or protocols differ from the data a model was trained or tested on. Distribution shift is a major reason AI tools can perform worse locally than in published studies.

New Technology Add-on Payment (NTAP): NTAP is a temporary Medicare payment to hospitals for qualifying new technologies. NTAP offsets hospital cost but is not the vendor’s price, so budgets should not treat it as a vendor discount.

Protected Health Information (PHI): PHI is identifiable patient health data protected under US privacy law. Any tool that receives PHI should first pass an institutional security and privacy review.

Which AI Medical Diagnostic Tool Is Right for You?

Key Insights

• The right AI medical diagnostic tool is the one whose verified FDA clearance matches your clinical job and whose evidence holds up on your own patients. No platform in this review leads every category, and every product carries a genuine limitation.
• Viz.ai has the strongest independent workflow evidence in this review, but a 2025 meta-analysis found no significant change in length of stay with Viz.ai use.
• Aidoc has the broadest explicitly listed acute-imaging clearances in this review, while Aidoc’s turnaround and length-of-stay outcomes are still vendor-reported.
• Qure.ai suits screening programs that can manage false positives. qXR’s 48.7% specificity at 95.5% TB sensitivity was slightly higher than an expert reader’s 42.2%.
• OpenEvidence and Isabel DDx Companion are clinical decision support, not cleared devices. PathAI and Paige have a narrower cleared scope than their broader product lines suggest.

A hub-and-spoke stroke network should start with Viz.ai and test it against RapidAI. A health system that needs many imaging algorithms under one governance layer should consider Aidoc. A TB or lung screening program should consider Qure.ai.

An individual clinician should weigh OpenEvidence’s free access against Isabel DDx Companion’s predictable pricing. A digitized pathology lab should compare PathAI AISight Dx with Paige Prostate Detect. Before signing any contract, buyers should complete these five steps:

• Buyers should get the 510(k) or De Novo number for every algorithm in the contract.
• Buyers should get a line-item list of included algorithms and hosted third-party algorithms.
• Buyers should confirm whether licensing is per-study, per-module or fixed.
• Buyers should run a retrospective validation and then a silent prospective pilot on local cases.
• Buyers should complete an institutional security and PHI review.

Local validation is the buyer’s job, not the regulator’s. A JAMA Network Open review found published clinical performance studies for only about half of 903 FDA-authorized AI devices, and only 2% of the devices were tested in randomized trials [Source: JAMA Network Open, accessed 2026].

Read PlugRoute’s full evaluation methodology, and see PlugRoute’s other independent healthcare AI reviews before your next vendor meeting. We update this guide quarterly. Last updated: November 2026.

Related reviews

• Best AI Patient Engagement & Operations Software in 2026
• Best Architecture Software in 2026
• Best Apparel Design Software in 2026
• Best Camp Management Software in 2026
• Best Airline Route Planning Software in 2026
• Best Connected Agriculture Software in 2026